US2016251429A1PendingUtilityA1
Neutralising antibody molecules having specificity for human il-17
Est. expiryNov 19, 2024(expired)· nominal 20-yr term from priority
A61P 37/02A61P 3/10A61P 9/10A61P 9/00A61P 7/02A61P 41/00A61P 43/00A61P 37/06A61P 31/10A61P 35/02A61P 31/00A61P 3/00A61P 35/00A61P 31/12A61P 33/00A61P 31/04A61P 29/00A61P 25/28A61P 17/06A61P 1/04A61P 19/10A61P 11/06A61P 1/02A61P 1/16A61P 1/18A61P 19/02A61P 19/08A61P 17/02C07K 2317/565C07K 2317/24C07K 2317/92A61K 2039/505C07K 2317/76C07K 16/244A61K 47/60C07K 2317/20C07K 2317/55C07K 16/464
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
Claims
exact text as granted — not AI-modified1 . A neutralising antibody having specificity for human IL-17, wherein the antibody binds the same epitope as an antibody comprising a light chain and a heavy chain, wherein the variable domain of the heavy chain comprises SEQ ID NO:5 for CDR-H1, SEQ ID NO:6 for CDR-H2, and SEQ ID NO:7 for CDR-H3 and wherein the variable domain of the light chain comprises SEQ ID NO:8 for CDRL1, SEQ ID NO:9 for CDR-L2, and SEQ ID NO:10 for CDR-L3.
Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.